Trevi Therapeutics, Inc.TRVI stock score: 40/100

$13.72 · +1.55% · Scored Nov 19, 2026

Technical
53
Fundamental
37
News
52

The reading

Trevi Therapeutics (TRVI) scores 40 out of 100, which reads weak, higher than 25% of Healthcare stocks and 23% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 37, technicals 53.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 47 and contrarian oscillators 53.

News sentiment is neutral at 52; it is shown, not counted in the composite.

Since Aug 22, 2026 the composite has ranged from 38 to 52, and it is down 10 points over the period.

About Trevi Therapeutics

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, to treat chronic cough. Nalbuphine acts on opioid receptors in the brain and peripheral nervous system, and it is approved in an injectable form for pain. Trevi’s lead program targets chronic cough in people with idiopathic pulmonary fibrosis, a progressive lung disease in which persistent cough is common and has no approved treatment. After positive mid-stage results, it has started late-stage trials in this indication, and it is also studying Haduvio in refractory chronic cough and in cough linked to other interstitial lung diseases. Trevi has no approved products, so it funds its research mainly through equity raises. If approved, Haduvio would earn money from product sales, either through Trevi’s own commercial team or through partners.

Trevi competes with other companies developing chronic cough treatments, including larger drugmakers working on drugs that act through other mechanisms. Its edge rests on a mechanism that acts on the brain’s cough reflex, clinical data showing reduced cough frequency, and a focus on patients with lung disease who have no approved options. Investors who follow TRVI stock tend to watch enrollment and results of its late-stage trials. Feedback from regulators on trial design is closely followed. Safety and tolerability data, cash runway and share dilution are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward TRVI’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

37

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

26 weighted scorers; 13 had no data today and are left out rather than counted as zero.

Technical · daily

46

Pulling it up

Holding it back

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Where the close sits against its 100-day SMA.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

61 weighted scorers; 4 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
52

Technical score by timeframe

ChartScoreWeight
Hourly611
Daily463
Weekly512
Monthly612

Composite score, last 90 days

05010040Aug 22, 2026Nov 19, 2026Aug 22, 2026: 50Aug 23, 2026: 50Aug 24, 2026: 50Aug 25, 2026: 49Aug 26, 2026: 49Aug 27, 2026: 49Aug 28, 2026: 47Aug 29, 2026: 47Aug 30, 2026: 47Aug 31, 2026: 46Sep 1, 2026: 47Sep 2, 2026: 49Sep 3, 2026: 52Sep 4, 2026: 48Sep 5, 2026: 48Sep 6, 2026: 48Sep 7, 2026: 48Sep 8, 2026: 48Sep 9, 2026: 46Sep 10, 2026: 45Sep 11, 2026: 45Sep 12, 2026: 45Sep 13, 2026: 45Sep 14, 2026: 45Sep 15, 2026: 44Sep 16, 2026: 44Sep 17, 2026: 45Sep 18, 2026: 45Sep 19, 2026: 45Sep 20, 2026: 45Sep 21, 2026: 45Sep 22, 2026: 46Sep 23, 2026: 46Sep 24, 2026: 45Sep 25, 2026: 44Sep 26, 2026: 43Sep 27, 2026: 43Sep 28, 2026: 44Sep 29, 2026: 45Sep 30, 2026: 44Oct 1, 2026: 44Oct 2, 2026: 43Oct 3, 2026: 43Oct 4, 2026: 43Oct 5, 2026: 42Oct 6, 2026: 41Oct 7, 2026: 41Oct 8, 2026: 41Oct 9, 2026: 42Oct 10, 2026: 42Oct 11, 2026: 42Oct 12, 2026: 42Oct 13, 2026: 41Oct 14, 2026: 40Oct 15, 2026: 40Oct 16, 2026: 40Oct 17, 2026: 40Oct 18, 2026: 40Oct 19, 2026: 40Oct 20, 2026: 42Oct 21, 2026: 43Oct 22, 2026: 43Oct 23, 2026: 42Oct 24, 2026: 42Oct 25, 2026: 41Oct 26, 2026: 41Oct 27, 2026: 45Oct 28, 2026: 43Oct 29, 2026: 45Oct 30, 2026: 43Nov 1, 2026: 45Nov 2, 2026: 45Nov 3, 2026: 42Nov 4, 2026: 46Nov 5, 2026: 42Nov 6, 2026: 45Nov 7, 2026: 46Nov 8, 2026: 46Nov 10, 2026: 47Nov 11, 2026: 48Nov 12, 2026: 38Nov 13, 2026: 39Nov 14, 2026: 39Nov 15, 2026: 39Nov 16, 2026: 39Nov 17, 2026: 39Nov 18, 2026: 39Nov 19, 2026: 40
Show the daily numbers
DateComposite
Nov 19, 202640
Nov 18, 202639
Nov 17, 202639
Nov 16, 202639
Nov 15, 202639
Nov 14, 202639
Nov 13, 202639
Nov 12, 202638
Nov 11, 202648
Nov 10, 202647
Nov 8, 202646
Nov 7, 202646
Nov 6, 202645
Nov 5, 202642
Nov 4, 202646
Nov 3, 202642
Nov 2, 202645
Nov 1, 202645
Oct 30, 202643
Oct 29, 202645
Oct 28, 202643
Oct 27, 202645
Oct 26, 202641
Oct 25, 202641
Oct 24, 202642
Oct 23, 202642
Oct 22, 202643
Oct 21, 202643
Oct 20, 202642
Oct 19, 202640
Oct 18, 202640
Oct 17, 202640
Oct 16, 202640
Oct 15, 202640
Oct 14, 202640
Oct 13, 202641
Oct 12, 202642
Oct 11, 202642
Oct 10, 202642
Oct 9, 202642
Oct 8, 202641
Oct 7, 202641
Oct 6, 202641
Oct 5, 202642
Oct 4, 202643
Oct 3, 202643
Oct 2, 202643
Oct 1, 202644
Sep 30, 202644
Sep 29, 202645
Sep 28, 202644
Sep 27, 202643
Sep 26, 202643
Sep 25, 202644
Sep 24, 202645
Sep 23, 202646
Sep 22, 202646
Sep 21, 202645
Sep 20, 202645
Sep 19, 202645
Sep 18, 202645
Sep 17, 202645
Sep 16, 202644
Sep 15, 202644
Sep 14, 202645
Sep 13, 202645
Sep 12, 202645
Sep 11, 202645
Sep 10, 202645
Sep 9, 202646
Sep 8, 202648
Sep 7, 202648
Sep 6, 202648
Sep 5, 202648
Sep 4, 202648
Sep 3, 202652
Sep 2, 202649
Sep 1, 202647
Aug 31, 202646
Aug 30, 202647
Aug 29, 202647
Aug 28, 202647
Aug 27, 202649
Aug 26, 202649
Aug 25, 202649
Aug 24, 202650
Aug 23, 202650
Aug 22, 202650

Key facts

Market cap
$2.0B
Sector
Healthcare
Industry
Biotechnology
Beta
1.12
Risk grade (1–10)
7
Next earnings
Nov 9, 2026

Questions

What is TRVI's stock rating today?

TRVI scores 40/100 (Weak) as of Nov 19, 2026: technical 53, fundamental 37, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.

What does Trevi Therapeutics do?

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, to treat chronic cough. Nalbuphine acts on opioid receptors in the brain and peripheral nervous system, and it is approved in an injectable form for pain.

Is TRVI stock a buy?

The score is not a buy or sell recommendation. A 40 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the TRVI score calculated?

87 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

TRVI stock score

HTML

<a href="https://stocksscores.com/stocks/trvi/"><img src="https://stocksscores.com/stocks/trvi/badge.svg" alt="TRVI stock score" height="20"></a>

Markdown

[![TRVI stock score](https://stocksscores.com/stocks/trvi/badge.svg)](https://stocksscores.com/stocks/trvi/)